6630-04-2

Basic information

• Product Name: 1,3-Bis(5-carboxypentyl)urea
• Synonyms: 1,3-Bis(5-carboxypentyl)urea;LXNSSMBDZOAFCT-UHFFFAOYSA-N
• CAS NO: 6630-04-2
• Molecular Formula: C₁₃H₂₄N₂O₅
• Molecular Weight: 288.3401
• Mol File: 6630-04-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 587.6°Cat760mmHg
• Flash Point: 309.2°C
• Appearance: /
• Density: 1.166g/cm³
• CAS DataBase Reference: 1,3-Bis(5-carboxypentyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Bis(5-carboxypentyl)urea(6630-04-2)
• EPA Substance Registry System: 1,3-Bis(5-carboxypentyl)urea(6630-04-2)

Safety Data

• Hazardous Substances Data: 6630-04-2(Hazardous Substances Data)

Usage

General Description

1,3-Bis(5-carboxypentyl)urea is a chemical compound with the molecular formula C13H22N2O6. It is a urea derivative that contains two carboxypentyl groups attached to the nitrogen atom in the urea backbone. 1,3-Bis(5-carboxypentyl)urea is commonly used as a crosslinking agent in the synthesis of hydrogels, which are highly absorbent polymers capable of holding large amounts of water. 1,3-Bis(5-carboxypentyl)urea is also used in the formulation of various personal care and cosmetic products, as well as in the production of pharmaceuticals and agricultural chemicals. Additionally, it has potential applications in drug delivery systems, tissue engineering, and biomedical devices due to its biocompatible and biodegradable properties.

Upstream product

• 3134-61-0 7-chloro-2,3,4,5-tetrahydro-azepine-1-carbonyl chloride 
• 6630-05-3 6,6'-thioureylene-di-hexanoic acid 
• 109817-68-7 6,6'-ureylene-di-hexanoic acid diethyl ester 
• 19494-73-6 1-[(2-oxazepan-1-yl)carbonyl]azepan-2-one 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 60-32-2 6-aminohexanoic acid 
• 75-44-5 phosgene 
• 860793-15-3 1,3-bis(5-ethoxycarbonyl-5-methylhexyl)urea 
• 4048-33-3 6-amino-1-hexanol 
• 100799-04-0 1,3-bis(6-hydroxyhex-1-yl)urea 
• 102-09-0 bis(phenyl) carbonate 

Downstream Products

• 6621-60-9 N,N'-bis(5-methoxycarbonylpent-1-yl)urea 
• 102895-88-5 6,6'-ureylene-di-hexanoic acid bis-cyclohexylamide 
• 1468-42-4 6-ureidohexanoic acid 
• 103045-22-3 N,N'-bis-(5-cyclohexylcarbamoyl-pentyl)-N-nitroso-urea 
• 496-46-8 glycoluril 

Relevant articles and documents

Modulation of Bambusuril Anion Affinity in Water

Neutral and negatively charged anion receptors functioning in pure water are rare in supramolecular chemistry. Moreover, studies on adjusting the affinity of such receptors toward anions in water are absent from the literature. Two new bambusurils, 1 a and 2 a, were prepared to demonstrate that the affinity of bambusurils towards anions can be altered by the length of carboxyalkyl groups attached to the macrocycles. The stability of the bambusuril complexes was further controlled by the pH value. The crystal structure of bambusuril 1 a was described, in which two carboxyalkyl arms fold into the macrocycle cavity, thus forming the intramolecular self-inclusion complex.

Urea and thiourea compounds and compositions for cholesterol management and related uses

The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.